IGC Pharma is a clinical-stage biotechnology company focused on developing pharmaceutical treatments for Alzheimer's disease and metabolic disorders. The company's lead program, IGC-AD1, is in Phase II clinical trials for agitation associated with dementia due to Alzheimer's. The company maintains a pipeline of pre-clinical candidates including TGR-63, IGC-M3, and LMP for Alzheimer's disease, as well as IGC-1C and IGC-1A for metabolic disorders and related conditions.
The company operates primarily in the United States and Colombia. IGC Pharma was incorporated in Maryland in 2005 under the name India Globalization Capital, Inc., before rebranding to its current name in March 2023. The company maintains headquarters in Potomac, Maryland, and operates with approximately 70 full-time employees.
As a clinical-stage company, IGC Pharma does not generate revenue from product sales. The organization is supported through capital raises and operates under the cost structure typical of development-stage pharmaceutical firms conducting clinical trials and preclinical research.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2025 | $-0.09 | $-0.09 | — | |
| 2024 | — | — | — | |
| 2023 | — | — | — | |
| 2022 | — | — | — | |
| 2021 | — | — | — | |
| 2020 | — | — | — | |
| 2019 | — | — | — | |
| 2018 | — | — | — | |
| 2017 | $-0.07 | $-0.07 | +58.8% | |
| 2016 | $-0.17 | $-0.17 | +45.2% | |
| 2015 | $-0.31 | $-0.31 | +16.2% | |
| 2014 | $-0.37 | $-0.37 | -15.6% | |
| 2013 | $-0.32 | $-0.32 | +0.0% | |
| 2012 | $-0.32 | $-0.32 | -18.5% | |
| 2011 | $-0.27 | $-0.27 | — |
| Report Date | Filed | Accession Number | |
|---|---|---|---|
| 2025-03-31 | 2025-06-27 | 0001185185-25-000706 | SEC ↗ |
| 2024-03-31 | 2024-06-24 | 0001185185-24-000650 | SEC ↗ |
| 2023-03-31 | 2023-07-07 | 0001185185-23-000693 | SEC ↗ |
| 2022-03-31 | 2022-06-23 | 0001185185-22-000768 | SEC ↗ |
| 2021-03-31 | 2021-06-14 | 0001185185-21-000802 | SEC ↗ |
| 2020-03-31 | 2020-07-13 | 0001185185-20-000984 | SEC ↗ |
| 2019-03-31 | 2019-06-14 | 0001185185-19-000890 | SEC ↗ |
| 2018-03-31 | 2018-06-21 | 0001185185-18-001155 | SEC ↗ |
| 2017-03-31 | 2017-07-14 | 0001185185-17-001544 | SEC ↗ |
| 2016-03-31 | 2016-07-14 | 0001185185-16-004982 | SEC ↗ |
| 2015-03-31 | 2015-07-14 | 0001185185-15-001808 | SEC ↗ |
| 2014-03-31 | 2014-07-15 | 0001185185-14-001804 | SEC ↗ |
| 2013-03-31 | 2013-07-16 | 0001185185-13-001473 | SEC ↗ |
| 2012-03-31 | 2012-07-16 | 0001185185-12-001484 | SEC ↗ |
| 2011-03-31 | 2011-07-14 | 0001185185-11-001000 | SEC ↗ |
| 2010-03-31 | 2010-07-14 | 0001185185-10-000790 | SEC ↗ |
| 2009-03-31 | 2009-07-14 | 0001185185-09-000666 | SEC ↗ |